Personal Care, Beauty & Cosmetics M&A and Valuation Multiples in Q2 2026
Beauty is the rare consumer sector where buyers pay for the promise, not just the product — and the market has never been clearer about which promises are worth paying for. Brand equity, efficacy and growth command the premium; commoditised hygiene and private-label manufacturing sit at the floor. Across 16 listed businesses the median trades at 10.8x EV/EBITDA 2026E, but the range runs from around 4x for a private-label hygiene manufacturer to 19x for L'Oréal. And in M&A, the whole sector re-rates upward: beauty deals have averaged roughly 15x EV/EBITDA — a five-turn premium to consumer M&A generally, and often far higher for scarce, high-growth brands — because acquirers are buying gross margin and growth they cannot build themselves.
The backdrop: a target-rich market re-rating around efficacy
Two forces define beauty in 2026. The first is the consumer's flight to efficacy and value: shoppers are trading down from prestige to "masstige" and mass, but they refuse to give up on results. Mass-market beauty grew around 4% in the first half of 2025 while prestige growth slowed to roughly 2%, with fragrance the bright spot across both. Brands that pair a credible efficacy story with an accessible price are winning; undifferentiated premium is under pressure.
The second is a wave of portfolio reshaping that has made the sector unusually target-rich. The majors are pruning: Kenvue has put its Skin Health & Beauty unit under strategic review, LVMH has explored a sale of its stake in Fenty Beauty, and a string of non-core brands are quietly on the block. At the same time, strategic buyers have re-entered with conviction and private equity is circling. The result is a buyer's-and-seller's market at once — plenty of assets in motion, and plenty of capital chasing the good ones.
That split — efficacy and brand equity prized, commodity discounted — runs straight through the comparable set below and is the single most useful lens for any owner trying to understand what their business is worth.
What the comparables say
Median EV/EBITDA 2026E by bucket, alongside the operating metrics that drive those multiples. The ranking tracks one thing above all: how much the end consumer actively wants — and trusts — the product, and how much pricing power that creates. Note how narrow the gap between the tiers has become: strong individual brands now matter more than the tier a business nominally sits in.
Personal Care, Beauty & Cosmetics — Median EV/EBITDA 2026E by Bucket
Median multiple shown as a horizontal bar, alongside the operating metrics that drive the ranking.
| Bucket | EV / EBITDA 2026E (median) | EBITDA Margin '26E | Rev Growth '26–28E |
|---|---|---|---|
| Prestige & Luxury Beauty | 14.7x | 20.5% | 5.6% |
| Mass Market Beauty & Personal Care | 12.1x | 23.3% | 3.0% |
| Fragrance Brands | 9.6x | 20.3% | 3.7% |
| Hygiene & Contract Manufacturing | 8.3x | 15.0% | 2.3% |
Prestige & luxury beauty — brand equity as the asset
A median of 14.7x for the businesses that own desire outright, though the internal spread is wide. L'Oréal (~19x) is the sector's quality benchmark and clear leader — diversified, innovation-led, consistently outgrowing the market. Estée Lauder (~14.7x) has re-rated as its turnaround takes hold, though it still carries heavy China exposure. e.l.f. Beauty (~12.3x) sits lowest despite the fastest growth in the set (~15%): the market has repriced the one-time disruptor as its hyper-growth phase matures and competition intensifies, a reminder that a growth multiple is only ever rented, never owned. What unites the bucket is ownership of brand and gross margin — but the gap between L'Oréal and e.l.f. shows the market now discriminates sharply on durability, not just tier.
Prestige & Luxury Beauty — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency.
| Company | Country | Mkt Cap (m, local ccy) | EV/EBITDA 2026E | EBITDA Margin 2026E | Rev Growth avg 26-28E |
|---|---|---|---|---|---|
| L'Oréal | France | EUR 205,000 | 19.0x | 22.5% | 5.6% |
| Estée Lauder | US | USD 32,500 | 14.7x | 18.5% | 6.0% |
| e.l.f. Beauty | US | USD 6,900 | 12.3x | 20.5% | 15.0% |
| Median | 14.7x | 20.5% | 5.6% |
Mass market beauty & personal care — scale and stability
A median of 12.1x, and the most striking feature of this refresh is how close the top of this bucket now sits to prestige. Church & Dwight (~17.5x), Colgate (~15.9x) and Procter & Gamble (~15.4x) trade like premium consumer staples, rewarded for scale, pricing power and defensive cash generation, with Church & Dwight now screening above every prestige name bar L'Oréal. Kenvue (~12.1x) sits mid-pack with its skin-health portfolio under review. The European names Henkel (~8.0x) and Beiersdorf (~7.6x), and Edgewell (~8.5x), trade lower on mix and growth. This is a bucket valued for durability — and right now the market is paying more for a dependable mass-market compounder than for a maturing prestige growth story.
Mass Market Beauty & Personal Care — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency.
| Company | Country | Mkt Cap (m, local ccy) | EV/EBITDA 2026E | EBITDA Margin 2026E | Rev Growth avg 26-28E |
|---|---|---|---|---|---|
| Church & Dwight | US | USD 22,800 | 17.5x | 24.5% | 3.2% |
| Colgate-Palmolive | US | USD 68,500 | 15.9x | 26.5% | 3.5% |
| Procter & Gamble | US | USD 358,000 | 15.4x | 27.5% | 3.4% |
| Kenvue | US | USD 42,000 | 12.1x | 24.0% | 2.6% |
| Edgewell Personal Care | US | USD 1,650 | 8.5x | 17.5% | 1.9% |
| Henkel | Germany | EUR 32,000 | 8.0x | 18.5% | 2.4% |
| Beiersdorf | Germany | EUR 24,500 | 7.6x | 18.5% | 3.8% |
| Median | 12.1x | 23.3% | 3.0% |
Fragrance brands — the licence discount
A median of 9.6x, below mass market, despite fragrance being the hottest category in beauty right now. The explanation is the business model. Interparfums (~12.2x), Puig (~9.6x) and Coty (~5.9x) are, to varying degrees, licensees — they rent brand names like Jimmy Choo, Gucci and Hugo Boss from fashion houses and distribute the scent, rather than owning the brand equity outright. The market discounts that licence dependency, contract-renewal risk and lower structural margin, even as the underlying category booms. The contrast is instructive: fragrance owned inside a prestige house (Dior at LVMH, YSL at L'Oréal) is valued at the top of the ladder, while fragrance rented by a listed licensee is valued near the bottom.
Fragrance Brands — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency.
| Company | Country | Mkt Cap (m, local ccy) | EV/EBITDA 2026E | EBITDA Margin 2026E | Rev Growth avg 26-28E |
|---|---|---|---|---|---|
| Interparfums | France | EUR 1,600 | 12.2x | 20.5% | 5.5% |
| Puig Brands | Spain | EUR 9,800 | 9.6x | 20.3% | 4.5% |
| Coty | US | USD 4,900 | 5.9x | 20.0% | 1.0% |
| Median | 9.6x | 20.3% | 3.7% |
Hygiene & contract manufacturing — the value floor
A median of 8.3x, the bottom of the ladder. Essity (~8.8x) in hygiene, Intercos (~8.3x) in contract manufacturing and Ontex (~4.2x) in private-label nappies and wipes are capital-intensive, low-margin, and — in the contract and private-label cases — one step removed from the consumer entirely. Intercos makes other companies' products; Ontex makes retailers' own-label. Without a brand or a clinical claim of their own, they capture little of the value they help create, and the multiple reflects it.
Hygiene & Contract Manufacturing — Listed peers ranked by EV/EBITDA 2026E. Market cap in millions of local currency.
| Company | Country | Mkt Cap (m, local ccy) | EV/EBITDA 2026E | EBITDA Margin 2026E | Rev Growth avg 26-28E |
|---|---|---|---|---|---|
| Essity | Sweden | SEK 190,000 | 8.8x | 17.0% | 2.4% |
| Intercos | Italy | EUR 1,200 | 8.3x | 15.0% | 4.5% |
| Ontex | Belgium | EUR 600 | 4.2x | 10.5% | 0.5% |
| Median | 8.3x | 15.0% | 2.3% |
Source: company filings / consensus estimates, refreshed July 2026. Shaded cells are at or above the peer-set median.
The valuation gap, priced by buyers
The same ladder shows up in what acquirers actually pay — but with a crucial twist: beauty M&A clears at a substantial premium to where the sector trades. Beauty deals averaged roughly 15x EV/EBITDA in 2025, well above the ~11x screen, because the economics of a beauty brand — 60-70%+ gross margins, above-market growth, emotional consumer loyalty — are worth more inside an acquirer's distribution machine than on a standalone screen.
The deals of the last three years split cleanly along the efficacy-and-brand line. At the top, strategics have paid full prices for scarce, high-growth, founder-led brands: L'Oréal acquired Medik8 and Aesop at around 20x EBITDA, e.l.f. bought rhode and Naturium at 14x and 21x, and Unilever paid ~18x for Paula's Choice and ~17x for the men's-grooming disruptor Dr. Squatch. The common thread is a differentiated, high-margin brand — most of these targets ran EBITDA margins of 20-50% — and disclosed EV/EBITDA multiples cluster around 20x, well above the screen, reflecting the premium acquirers will pay to own efficacy and brand equity. Activity has carried firmly into 2026: L'Oréal completed its ~$4.65bn acquisition of Kering Beauté (anchored by the Creed fragrance house and 50-year Gucci, Bottega Veneta and Balenciaga licences) at around 20x, Estée Lauder bought India's Forest Essentials at ~21x and Henkel acquired the hair-care brand Olaplex at ~15x, and Estée Lauder and Puig held (ultimately abandoned) talks over a ~$40bn combination — together a clear signal of how aggressively the majors are consolidating around fragrance and efficacy. At the value end, the logic is different again: hygiene consolidation is about scale and synergy, not brand — Essity's bolt-ons of Legacy Converting and Edgewell's feminine-care brands both cleared around 12x, dropping into single digits once run-rate synergies are counted.
For UK and European owners, the read-through is clear and encouraging: a differentiated beauty or personal-care business — one with genuine efficacy, a loyal consumer, strong gross margin and above-market growth — sits in the most sought-after M&A category in consumer, and will attract both strategic and financial competition. The premium is reserved for brands that own something a buyer cannot replicate.
Precedent transactions
Beauty & Personal Care — Recent Precedents
Selected announced and completed deals, grouped by bucket. Deal values in millions of local currency at announcement.
1 13.9x including a $200m performance earn-out; 11.1x on the $1.0bn upfront.
2 16.0x including a $180m performance earn-out; 12.7x on the $700m upfront.
3 Edgewell Feminine Care (Carefree, Stayfree, Playtex): $340m on ~$28m EBITDA = 12.1x; ~8.3x including estimated run-rate synergies (~$41m combined EBITDA).
Source: company announcements, Capstone Partners and DC Advisory beauty M&A reviews, and press reports. Headline EV/EBITDA at announcement where disclosed. EBITDA margin is the target's at deal. Illustrative — does not constitute advice.
What this means if you are considering a sale
Brand strength and efficacy set your multiple, not category. The 4x-to-19x spread on the screen — and the way a mass-market compounder like Church & Dwight now out-trades a maturing prestige name — shows the market prices durability and brand equity, not the tier a business nominally sits in. A differentiated, high-margin, growing brand is valued like a different business from a commoditised or licence-dependent one, even in the same aisle. Establishing where your business truly sits is the single most important input into the valuation.
Beauty is the most sought-after category in consumer M&A. With sector deals clearing a premium to the public screen — frequently around 20x for scarce, high-margin brands — owners of genuinely differentiated beauty and personal-care businesses are in an unusually strong position. Gross margin and growth are the currency: a 60-70% gross-margin brand growing above market attracts a fundamentally different conversation from a low-margin, low-growth one.
Two buyer pools are competing right now. Strategics are paying premium prices to fill portfolio gaps and buy growth they cannot build; private equity and platform aggregators are active at the smaller end, backing founders for a second act. A well-run process that engages both — and that presents a clean efficacy and brand-equity story — will almost always beat a bilateral conversation.
Frequently asked questions about beauty & personal care valuation multiples
What multiple do beauty and personal care companies sell for?
Across 16 listed personal care, beauty and cosmetics peers the median is around 11x EV/EBITDA 2026E, but the range runs from roughly 4x for commodity hygiene and private-label manufacturing to about 19x for a sector leader like L'Oréal. In M&A, beauty has averaged around 15x EV/EBITDA — a five-turn premium to consumer M&A generally — and disclosed multiples for scarce, high-margin brands have recently clustered around 20x EBITDA.
Why does beauty trade at a premium to other consumer sectors?
Gross margin and growth. Beauty brands routinely run 60–70%+ gross margins, well above broad consumer, and that high gross profit funds the marketing that drives above-market growth. Acquirers will pay more per dollar of revenue because a beauty brand run through their distribution machine generates more profit than almost any other consumer category.
Which parts of beauty command the highest valuations?
Prestige and luxury beauty brands that own their equity sit at the top, led by names like L'Oréal. The best mass-market compounders — Church & Dwight, Colgate, P&G — now trade right alongside them on premium staples multiples. Fragrance-brand licensees trade at a discount for their licence dependency, and commodity hygiene and contract manufacturing sit at the floor.
Why do listed fragrance companies trade below mass-market beauty?
Because most listed fragrance names are licensees rather than brand owners — they rent names like Gucci or Jimmy Choo from fashion houses and distribute the scent. The market discounts that licence dependency, renewal risk and lower structural margin, even as the underlying category booms. Fragrance owned inside a prestige house is valued at the top of the ladder.
Is now a good time to sell a beauty or personal care business?
The sector is unusually active. Consumer demand is resilient, the majors are reshaping portfolios and creating a target-rich market, and both strategics and private equity are deploying capital. Differentiated, high-margin, growing brands are attracting strong competition. The decisive factor is less market timing than how clearly an owner can evidence efficacy, brand equity, gross margin and durable growth.
Free business valuation & exit readiness assessment
Deal Ascent advises UK family- and founder-owned businesses on sale processes, acquisitions and strategic options across the consumer, beauty, food and industrial sectors. If you would like a confidential view on how your business would be positioned and valued in the current market, we would be glad to talk.
This article is intended for information purposes only and does not constitute financial, tax or legal advice. Valuation multiples are based on listed peer group consensus estimates as of Q2 2026 and are provided for directional context only. Private company transactions will differ. Specific professional advice should be sought before making any business or financial decisions.